HER-2阴性胃癌的分子靶向治疗

Molecular targeted therapy for HER-2 negative gastric cancer

目前分子靶向治疗已成为胃癌研究领域的热点。人类表皮生长因子受体-2（HER-2）靶基因的发现及相关靶向治疗已在临床广泛应用，而 HER-2阳性的发病人群＜20％。除 HER-2外，针对肿瘤细胞生长、浸润及血管生成等的靶点和靶向治疗值得关注。一些分子靶向药物应用于临床并呈现良好的疗效，为 HER-2阴性胃癌患者带来希望。

Molecular targeted treatment has become hotspot in the gastric cancer research.Human epi-dermal growth factor receptor-2（HER-2）target genes found to treatment has widely used in clinical practice, and HER-2 positive incidence of less than 20%.In addition to HER-2,understanding the molecular pathways that characterize in cell growth,invasion and angiogenesis of targets and targeted therapy are worthy for atten-tion.There are some molecular targeted drugs have been used to treat tumors,and patients can benefit from the treatment which brings new hope for patients with HER-2 negative gastric cancer.